Physician profile
Sandy K Yip
NPI 1013070804
$5,200.87
in general payments reported to CMS, 2019-2025
27 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $390 · 2021: $345 · 2022: $481 · 2023: $641 · 2024: $956 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,509 · Education: $189 · Consulting Fee: $88.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,509.26 |
| Education | $189.22 |
| Consulting Fee | $88.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $855.85 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $764.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $526.73 | 2020-2025 | Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $496.78 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genzyme Corporation | $420.45 | 2020-2025 | |
| Csl Behring | $410.60 | 2019-2024 | Haegarda, Hizentra |
| Blueprint Medicines Corporation | $332.53 | 2022-2024 | Ayvakit |
| Biocryst US Sales Co., LLC | $193.89 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $189.82 | 2019-2023 | Cutaquig |
| Optinose US, INC. | $149.52 | 2020-2025 | |
| Pharming Healthcare, INC. | $113.53 | 2023-2025 | Ruconest |
| Amgen INC. | $111.95 | 2022-2025 | Tezspire |
| Adma Biomanufacturing LLC | $88.44 | 2025 | |
| Novartis Pharmaceuticals Corporation | $82.85 | 2025 | |
| Tersera Therapeutics LLC | $75.91 | 2024-2025 | Quzyttir |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $62.58 | 2019-2024 | Xolair |
| Galderma Laboratories, L.P. | $59.86 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $55.99 | 2025 | |
| Aimmune Therapeutics, INC. | $46.79 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $29.04 | 2025 | Dupixent |
| Abbvie INC. | $28.81 | 2022 | |
| Shire North American Group INC | $23.04 | 2019 | |
| Ionis Pharmaceuticals, INC. | $19.94 | 2025 | Dawnzera |
| X4 Pharmaceuticals, INC. | $16.52 | 2025 | Xolremdi |
| Grifols USA, LLC | $16.45 | 2024 | Prolastin-C Liquid |
| Azurity Pharmaceuticals, INC. | $16.28 | 2025 | Alvesco |
| Kaleo, INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.